An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 65 (4), 473-496
- https://doi.org/10.2165/00003495-200565040-00004
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- A survey of British rheumatologists' DMARD preferences for rheumatoid arthritisRheumatology, 2003
- Responsiveness of Health Status Measures and Utility-based Methods in Patients with Rheumatoid ArthritisClinical Rheumatology, 2002
- Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysisHealth Economics, 2002
- A Review of the Direct Costs of Rheumatoid ArthritisPharmacoEconomics, 2001
- Factors predicting response to treatment in rheumatoid arthritis: The importance of disease durationArthritis & Rheumatism, 2000
- Measuring the Effects of Medication Use on Health-Related Quality of Life in Patients with Rheumatoid ArthritisPharmacoEconomics, 1999
- Special article the economic cost and social and psychological impact of musculoskeletal conditionsArthritis & Rheumatism, 1995
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995
- Assessment of Quality of Life in Rheumatoid ArthritisPharmacoEconomics, 1994